scout
Opinion|Videos|December 13, 2023

Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

The panel reviews results from the ATTEND and DUO-E trials in advanced endometrial cancer, suggesting pembrolizumab remains the standard for the dMMR patient subset while combinations with PARP inhibitors may improve outcomes in pMMR.

Episodes in this series

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME